Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus—do baseline resistance‐associated substitutions matter? Authors' reply

Abstract

LINKED CONTENT This article is linked to Singh et al and Kwong and Kwo papers. To view these articles, visit https://doi.org/10.1111/apt.15633 and https://doi.org/10.1111/apt.15656.

Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority—authors' reply

“…Considering the high effectiveness of this therapy, pre‐testing for the presence of baseline RAS may only hinder the access to therapy. For these reasons, baseline testing for g/p before initiation of therapy may not be necessary 4,5 …”